about
Neurocognitive Impairment in Obstructive Sleep ApneaRationale and design of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis. Alpha-1 protocolCyst-based measurements for assessing lymphangioleiomyomatosis in computed tomography.Design of the Endobronchial Valve for Emphysema Palliation Trial (VENT): a non-surgical method of lung volume reduction.Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study.Management of spontaneous pneumothorax: an American College of Chest Physicians Delphi consensus statement.Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trialCyclophosphamide versus placebo in scleroderma lung disease.The social environment and illness uncertainty in chronic obstructive pulmonary disease.Unilateral pulmonary artery aplasia in a pregnant patientIs PiSS Alpha-1 Antitrypsin Deficiency Associated with Disease?Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study.Genetics' influence on patient experiences with a rare chronic disorder: a photovoice study of living with alpha-1 antitrypsin deficiency.Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe alpha-1 antitrypsin deficiencyInterstitial lung disease in the patient who has connective tissue disease.Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.Association of cigarette smoking and CRP levels with DNA methylation in α-1 antitrypsin deficiency.IL10 polymorphisms are associated with airflow obstruction in severe alpha1-antitrypsin deficiency.Alcohol use predicts ER visits in individuals with alpha-1 antitrypsin deficiency (AATD) associated COPDMonitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelinesDifferences in adjustment between individuals with alpha-1 antitrypsin deficiency (AATD)-associated COPD and non-AATD COPD.The prospective association of perceived criticism with dyspnea in chronic lung disease.alpha1-Antitrypsin augmentation therapy for PI*MZ heterozygotes: a cautionary note.Development of predictive models for airflow obstruction in alpha-1-antitrypsin deficiency.Expanded carrier screening panels-does bigger mean better?Prospective impact of illness uncertainty on outcomes in chronic lung disease.Segmental approach to lung volume reduction therapy for emphysema patients.Impact of medications on cognitive function in obstructive sleep apnea syndrome.Aclidinium bromide plus formoterol for the treatment of chronic obstructive pulmonary disease.Radiation therapy for palliation of Eisenmenger's syndrome-associated painful splenomegaly.Failure of the circulatory system limits exercise performance in patients with systemic sclerosis.Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival.Opportunities and challenges in the study of pulmonary arterial hypertension.Detection of alpha-1 antitrypsin deficiency by respiratory therapists: experience with an educational program.Baseline regional perfusion impacts exercise response to endobronchial valve therapy in advanced pulmonary emphysema.Effect of obstructive sleep apnea treatment on mail-in cognitive function screening instrument.Multi-center study: the biochemical efficacy, safety and tolerability of a new alpha1-proteinase inhibitor, Zemaira.Adverse events during the Scleroderma Lung Study.Results of a survey of patients with alpha-1 antitrypsin deficiency.Safety and pharmacokinetics of 120 mg/kg versus 60 mg/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: a multicenter, randomized, double-blind, crossover study (SPARK).
P50
Q22241404-25E36079-8935-4B97-8427-D75F94AE6401Q23911017-7C5CE832-2013-4F09-8BFE-042EB6F1845AQ30952452-584628A5-A1A0-40DD-9D7C-41970B573F4BQ33294784-240FA494-1128-4C50-9725-5ABABAD7A4BBQ33710034-67B38CDD-D7AA-468D-AA9C-6C243486D94DQ33932868-17FF45E1-9B06-480C-8F4B-BACF631E811EQ34380247-45E690D3-6016-4677-A31B-B0323F2D741DQ34540647-7FC85EA7-A717-4722-A090-48D6F35EB4A9Q34899687-89F9990F-967B-495B-A86A-90FD492BB36BQ34923012-920A4BEF-DACA-4192-A78B-CC42B0749048Q34997267-C73FEB07-B185-4EBB-9699-265F3CF0B389Q35538141-0A8BF931-1D79-4994-B78E-D18890949D51Q35623122-C7DBA1E0-D823-4CE2-A5CA-824B29F7B694Q35837259-B5FAD015-0820-4E8A-BCFC-01A21F009568Q35872269-4AA465A2-78DC-4949-9D62-00B13519BF83Q36145795-CD5798B8-0901-472E-B811-3DBE7F3F566DQ36149225-ED64C968-D2CF-4EB2-ACC9-243E2EB858D7Q36330718-E504AB16-C528-47C2-8294-0F01304DD5DDQ36701417-323A7538-7EB2-4AB1-A524-180B3FAD7F2DQ36724093-43925F94-E08B-4DDC-AFF4-7C0368424B42Q36739873-CB4497FD-013E-4CC8-A3F9-53C77EF68293Q36780926-DA39D25A-74BC-4D0C-89F7-4FE19E6CF3F6Q37289632-B608BEB1-4EC3-482A-99F6-9BA12462B453Q37395410-8A4845B7-64E9-4797-8F51-447164E45465Q37639425-554230F7-C525-4175-A877-A02DE438CB44Q37663978-06664852-DDC6-497F-AE43-7B2351148A00Q38286977-C5122FBE-A05D-4D0C-8E24-38EBDEE80046Q38310541-D0F0873E-7A4D-40B0-A557-5E1C7EFBE634Q38322305-87ED6F9A-EA26-496D-B6B9-7B87C2C39F17Q39323169-5F2E9E60-AD87-4456-A063-71E0EC429A0BQ42607833-94B3E82A-8DF3-4921-A5A0-FA574281C78BQ42662066-38275484-2D48-4FCF-A9BB-308834A4F640Q44069499-6FEE5AC6-2702-4025-8B75-9C398058132DQ44305589-BB0FF834-722F-4F30-9502-09F1D0EA9107Q45883894-7DDDB228-D467-4D39-8555-98F7B48E8898Q46338334-7B1F9B7F-15AB-4A61-9C29-BA66B06C7867Q46504750-979DFA15-8D7F-4712-A21B-D97D87394C04Q46532900-EF32FA64-F43B-499E-A3E0-E670037A231AQ46686624-16DCB886-7423-4155-A4ED-916319080CC5Q46774150-160F5AC6-E483-48DF-9AF0-4C503A12BC5D
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Charlie Strange
@ast
Charlie Strange
@en
Charlie Strange
@es
Charlie Strange
@nl
Charlie Strange
@sl
type
label
Charlie Strange
@ast
Charlie Strange
@en
Charlie Strange
@es
Charlie Strange
@nl
Charlie Strange
@sl
altLabel
C Strange
@en
C. Strange
@ast
C. Strange
@en
C. Strange
@es
C. Strange
@nl
C. Strange
@sl
Strange C
@en
Strange C.
@en
Strange
@en
prefLabel
Charlie Strange
@ast
Charlie Strange
@en
Charlie Strange
@es
Charlie Strange
@nl
Charlie Strange
@sl
P106
P1153
55141368800
P31
P496
0000-0002-8109-8067